Since assuming his role as COO at Fox Chase Cancer Center in 2021, Mr. Helmke has driven growth and transformation, including an extraordinary 30% growth in patient volumes over three years, far surpassing the post-Covid gains of other National Cancer Institute-designated cancer centers. Mr. Helmke has expanded Fox Chase’s reach with new facilities in underserved areas, including a campus in Voorhees, N.J. and a state-of-the-art home for the Fox Chase–Temple Urologic Institute. His data-driven approach has streamlined clinical trial approvals, cutting the process from over 200 days to less than 90 and enhancing Fox Chase’s reputation for advancing cancer care. These efforts have catapulted Fox Chase back onto the U.S. News & World Report “best hospitals” list, now ranked No. 33 in cancer and No. 19 in urology for 2024-25.
